- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT00075439
Gefitinib in Treating Patients With Progressive Metastatic Neuroendocrine Tumors
A Phase II Trial of ZD1839 (Iressa®) in Metastatic Neuroendocrine Tumors
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Descripción detallada
PRIMARY OBJECTIVES:
I. To determine the 6 month progression free survival rate in patients with progressive, advanced neuroendocrine tumors treated with ZD1839.
SECONDARY OBJECTIVES:
I. Objective tumor response rate. II. Progression free survival and time to progression. III. Improvement in circulating hormone levels. IV. Overall survival V. We will explore the molecular characterization of these tumors in attempt to understand the role of EGFR expression and its inhibition with ZD1839 in neuroendocrine tumors. The measurements will be performed on pretreatment and post-treatment tumor biopsies when possible: EGFR expression and gene amplification (IHC for EGFR and phosphorylated EGFR, ISH for gene amplification); Activation of the Ras/Raf/MAPK pathway (IHC for phosphorylated MAPK); Cell proliferation (Ki-67 staining); Apoptosis (TUNEL assay).
OUTLINE: This is a multicenter study. Patients are stratified according to disease type (carcinoid vs islet cell and other neuroendocrine tumors).
Patients receive oral gefitinib once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Patients are followed every 3 months until disease progression and then every 6 months for up to 2 years from study entry.
Tipo de estudio
Inscripción (Anticipado)
Fase
- Fase 2
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
Minnesota
-
Rochester, Minnesota, Estados Unidos, 55905
- Mayo Clinic
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Histologically confirmed metastatic neuroendocrine neoplasms or histologic confirmation of primary neuroendocrine tumor with clear clinical evidence of metastases
- Measurable disease
Radiographic evidence of disease progression, following any prior systemic therapy, chemoembolization, embolization, or observation; for eligibility purposes, disease progression will be defined as follows:
Either of the following documented by comparison of the on-study radiographic assessment with a prior assessment of the same type performed within the previous 60 calendar weeks:
- Appearance of a new lesion
- At least 20% increase in the longest diameter (LD) of any previously documented lesion or an increase in the sum of the LDs of multiple lesions in aggregate of 20%
- ≥4 weeks from the completion of major surgery, chemotherapy or other systemic therapy and hepatic artery embolization/chemoembolization to study registration
- ≥3 weeks from the completion of radiation therapy to study registration
- Recovered sufficiently from side effects of prior therapy
- Absolute neutrophil count (ANC) ≥ 1000/mm3
- PLT ≥ 75,000/ mm3
- Hgb ≥ 8.0 g/dL
- Total bilirubin ≤ 2 x upper normal limit (UNL)
- Alkaline phosphatase ≤ 3 x UNL (5 x UNL if liver metastases present)
- AST ≤ 3 x UNL (≤ 5 x UNL if liver metastases present)
- Creatinine ≤ 1.5 x UNL
- ECOG performance score (ps) ≤ 2
- Life expectancy ≥ 24 weeks
- Capable of understanding the investigational nature, potential risks and benefits of the study and able to provide valid informed consent
Exclusion Criteria:
- Thyroid carcinoma of any histology or pheochromocytoma/paraganglioma
Any of the following as this regimen may be harmful to a developing fetus or nursing child:
- Pregnant women
- Breastfeeding women
- Men or women of childbearing potential or their sexual partners who are unwilling to employ adequate contraception (condoms, diaphragm, birth control pills, injections, intrauterine device [IUD], surgical sterilization, subcutaneous implants, or abstinence, etc.)
- NOTE: The effects of the agent(s) on the developing human fetus at the recommended therapeutic dose are unknown
- Anaplastic or high-grade histology
Any of the following prior therapies:
- > 1 prior systemic chemotherapy regimen (chemoembolization not counted as systemic chemotherapy)
- Prior EGFR targeted regimen (e.g. OSI-774, EKB-569, ZD1839)
- < 4 weeks from last Interferon injection
- < 2 weeks from last octreatide short acting injection or < 6 weeks long acting injection; Note: concurrent octreatide allowed if stable dose has been administered for ≥1 month, there is documented tumor progression on the current dose, and there is no current plan for increasing dose • Other concurrent treatment considered investigational
- Concurrent chemotherapy or radiation therapy
Any of the following:
- Gastrointestinal tract disease resulting in an inability to take oral medication (e.g. dysphagia or inability to swallow capsules intact).
- Requirement for IV alimentation
- Prior procedures clearly adversely affecting intestinal absorption
- Active peptic ulcer disease
- Failure to fully recover from adverse effects of prior therapies regardless of interval since last treatment
Known abnormality of cornea, such as:
- History of dry eye syndrome or Sjogren syndrome
- Congenital abnormality
- Abnormal slit-lamp examination using a vital dye (e.g.: fluorescein or Bengal-rose)
- Abnormal corneal sensitivity test (Schirmer test)
Uncontrolled intercurrent illness including, but not limited to:
- Ongoing or active infection
- Symptoms of congestive heart failure
- Unstable angina pectoris, cardiac arrhythmia
- Psychiatric illness/social situation that would limit compliance with study requirement
- Known brain metastases; Note: These patients are excluded from this clinical trial because of their poor prognosis and because they often develop progressive neurologic dysfunction that would confound the evaluation of neurologic and other adverse events
- Known HIV-positive patients receiving combination anti-retroviral therapy; Note: These patients are excluded from the study because of possible pharmacokinetic interactions with ZD1839 and because patients with immune deficiency are at increased risk of lethal infections when treated with marrow-suppressive therapy; appropriate studies will be undertaken in patients receiving combination and anti-retroviral therapy when indicated
- Concurrent or recent use (≤ 7 days prior to ZD1839 administration) of phenytoin, carbamazepine, barbiturates, rifampicin, oxcarbazepine, rifapentine, modafinil, or St. John's Wort; Note: Because these drugs induce CYP3A4 enzymes and can cause reductions in ZD1839 plasma concentrations below levels thought to be biologically active, patients with concurrent or recent use of these drugs are excluded from the study
- History of other invasive malignancy ≤ the previous 3 years, except for adequately treated basal cell or squamous cell skin cancer, or carcinoma in situ of the cervix
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: N / A
- Modelo Intervencionista: Asignación de un solo grupo
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
---|---|
Experimental: Arm I
Patients receive oral gefitinib once daily on days 1-28.
Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
|
Estudios correlativos
Administrado oralmente
Otros nombres:
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
---|---|---|
Proportion of patients progression-free at 6 months
Periodo de tiempo: At 6 months
|
If patients are lost to follow-up or discontinue active monitoring prior to 6 months post-registration, we will consider censoring them for the evaluation of the primary endpoint.
Here, Kaplan-Meier methodology will be used to estimate the final success proportion (ie, 6 month success rate with a 95% confidence interval).
Otherwise, ninety-five percent confidence intervals for the true success proportion will be calculated according to the approach of Duffy and Santner.
|
At 6 months
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
---|---|---|
Incidence of adverse events graded according to NCI CTCAE version 3.0
Periodo de tiempo: Up to 2 years
|
The maximum grade for each type of toxicity will be recorded for each patient, and frequency tables will be reviewed to determine toxicity patterns.
|
Up to 2 years
|
Confirmed tumor response to treatment will be evaluated and will be considered a PR or CR on consecutive evaluations at least 4 weeks apart
Periodo de tiempo: Up to 2 years
|
The proportion of responses will be evaluated and will be tabulated.
Assuming a binomial distribution for the incidence of response, 95% confidence intervals will also be generated.
|
Up to 2 years
|
Survival time
Periodo de tiempo: Time from registration to death due to any cause, assessed up to 2 years
|
The distribution of survival time will be estimated using the method of Kaplan-Meier.
|
Time from registration to death due to any cause, assessed up to 2 years
|
Time to disease progression
Periodo de tiempo: Time from randomization to documentation of disease progression, assessed up to 2 years
|
The distribution of time to progression will be estimated using the method of Kaplan-Meier.
|
Time from randomization to documentation of disease progression, assessed up to 2 years
|
Duration of response
Periodo de tiempo: Date from which the patient's objective status is first noted to be either a CR or PR to the date progression is documented, assessed up to 2 years
|
This data will be descriptively summarized and graphically evaluated.
|
Date from which the patient's objective status is first noted to be either a CR or PR to the date progression is documented, assessed up to 2 years
|
Time to treatment failure
Periodo de tiempo: Time from the date of registration to the date at which the patient is removed from treatment due to progression, toxicity, refusal, or death, assessed up to 2 years
|
Time from the date of registration to the date at which the patient is removed from treatment due to progression, toxicity, refusal, or death, assessed up to 2 years
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Timothy Hobday, Mayo Clinic
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio
Finalización primaria (Actual)
Finalización del estudio
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Estimar)
Actualizaciones de registros de estudio
Última actualización publicada (Estimar)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
- Enfermedades del Sistema Digestivo
- Procesos Patológicos
- Neoplasias por tipo histológico
- Neoplasias por sitio
- Adenocarcinoma
- Carcinoma
- Neoplasias Glandulares y Epiteliales
- Enfermedades del sistema endocrino
- Atributos de la enfermedad
- Neoplasias del Sistema Digestivo
- Enfermedades Gastrointestinales
- Neoplasias de glándulas endocrinas
- Tumores neuroectodérmicos
- Neoplasias De Células Germinales Y Embrionarias
- Neoplasias De Tejido Nervioso
- Enfermedades pancreáticas
- Adenoma
- Carcinoma Neuroendocrino
- Neoplasias pancreáticas
- Adenoma, Célula De Los Islotes
- Neoplasias
- Reaparición
- Neoplasias Gastrointestinales
- Tumores neuroendocrinos
- Tumor carcinoide
- Síndrome Carcinoide Maligno
- Carcinoma De Células De Los Islotes
- Insulinoma
- Gastrinoma
- Glucagonoma
- Somatostatinoma
- Vipoma
- Mecanismos moleculares de acción farmacológica
- Inhibidores de enzimas
- Agentes antineoplásicos
- Inhibidores de la proteína quinasa
- Gefitinib
Otros números de identificación del estudio
- NCI-2012-02796
- N01CM62205 (Subvención/contrato del NIH de EE. UU.)
- MC0279
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
producto fabricado y exportado desde los EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .
Ensayos clínicos sobre análisis de biomarcadores de laboratorio
-
ORIOL BESTARDTerminadoTrasplante de riñón | Infección por CMVEspaña, Bélgica
-
Vanderbilt University Medical Center4DMedicalTerminado
-
Central and North West London NHS Foundation TrustBritish HIV Association (BHIVA)Aún no reclutandoInfecciones por VIH | Hepatitis B
-
Johns Hopkins UniversityReclutamiento
-
University of MiamiActivo, no reclutando
-
Hvidovre University HospitalElsassFondenTerminadoAcidosis metabólica del recién nacidoDinamarca
-
Rio de Janeiro State UniversityCoordenação de Aperfeiçoamento de Pessoal de Nível Superior.; Conselho Nacional... y otros colaboradoresTerminadoEnfermedades cardiovasculares | Deficiencia de vitamina D | Condiciones relacionadas con la menopausiaBrasil